Usefulness of specific OA biomarkers, thrombin-cleaved osteopontin, in the posterior cruciate ligament OA rabbit model
Usefulness of specific OA biomarkers, thrombin-cleaved osteopontin, in the posterior cruciate ligament OA rabbit model
复制标题
特定 OA 生物标志物(凝血酶裂解骨桥蛋白)在后交叉韧带 OA 兔模型中的用途
DOI:
10.1016/j.joca.2012.09.006
复制
发表时间:
2013-01-01
影响因子:
7
通讯作者:
Lei, G. H.
中科院分区:
文献类型:
--
作者:
Gao, S. G.;Cheng, L.;Lei, G. H.
Objective: We undertook this study to determine whether thrombin-cleaved osteopontin (OPN) in synovial fluid (SF) represents a useful marker of osteoarthritis (OA) progression in the posterior cruciate ligament transection (PCLT) OA rabbit model.Method: PCLT was performed on the right knee joints of 48 rabbits. The rabbits were then sacrificed separately at 4, 8, 16, and 24 weeks post-surgery, when the joint was harvested and macroscopic and histological assessments of articular cartilage were performed. Thrombin-cleaved OPN product in SF was determined using Western blotting and the levels were measured using an enzyme-linked immunoassay.Results: The macroscopic and histological scores for PCLT knees were already elevated 4 weeks after surgery and increased with time. Western blotting showed the presence of thrombin-cleaved OPN in SF from PCLT knees. Thrombin-cleaved OPN levels in SF were elevated at 4 weeks (P < 0.001) and were elevated peaking at 24 weeks (P < 0.00001) after PCLT compared to baseline. A positive significant correlation was found between thrombin-cleaved OPN levels and the macroscopic scores (8 weeks: rho = 0.695, P = 0.012; 16 weeks: rho = 0.751, P = 0.005; 24 weeks: rho = 0.660, P = 0.020). Furthermore, the same correlation was noted between thrombin-cleaved OPN levels and the histological scores (4 weeks: rho = 0.609, P = 0.036; 8 weeks: rho = 0.662, P = 0.019; 16 weeks: rho = 0.827, P = 0.001; 24 weeks: rho = 0.813, P = 0.001).Conclusion: In this rabbit model of PCLT, thrombin-cleaved OPN levels in SF appear to provide a useful marker of OA disease severity and progression. Crown Copyright (C) 2012 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. All rights reserved.